WO2016068160A1 - 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 - Google Patents
局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 Download PDFInfo
- Publication number
- WO2016068160A1 WO2016068160A1 PCT/JP2015/080316 JP2015080316W WO2016068160A1 WO 2016068160 A1 WO2016068160 A1 WO 2016068160A1 JP 2015080316 W JP2015080316 W JP 2015080316W WO 2016068160 A1 WO2016068160 A1 WO 2016068160A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipoplex
- phosphatidylcholine
- shrna
- cancer
- dope
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Definitions
- the present invention relates to a novel method for producing a lipoplex for local administration and an antitumor agent using the lipoplex.
- Liposomes are composed of phospholipids that make up the cell membranes of living organisms, have high biocompatibility, and can be transported in vivo while protecting drugs and active ingredients from degrading enzymes. It is attracting attention as.
- RNAi molecules that cause RNA interference are attracting attention as useful tools for treating tumors and the like, and various RNAi molecules that can suppress tumor growth.
- RNAi RNAi molecules that cause RNA interference
- a method of delivering an RNAi molecule as an active ingredient to a tumor cell using a complex (lipoplex) composed of an RNAi molecule and a lipid mixture has been developed (Non-patent Documents 1-3).
- RNAi molecule that targets a thymidylate synthase (hereinafter referred to as “TS”) involved in tumor growth (Patent Document 1).
- TS thymidylate synthase
- a complex lipoplex loaded on a cationic lipid mixture having a predetermined ratio, for example, by intravenous administration, the tumor can be inhibited from growing by expressing it, and further, It has been reported that by using plexes together with chemotherapeutic agents, the targeting efficiency to tumors can be increased and the antitumor effect by RNAi molecules can be significantly improved (Patent Document 2).
- a method for preparing a lipid mixture includes a step of previously dissolving phospholipids as constituents in an organic solvent such as chloroform or cyclohexane.
- an organic solvent such as chloroform or cyclohexane
- a large-scale facility such as a hazardous material handling facility or an explosion-proof device is required.
- the hospital drug department prepares an aqueous solution of RNAi molecules before administration to cancer patients, separately prepares a lipid mixture, and then mixes both. It requires a complicated process and requires a lot of labor.
- the present invention uses a large amount of an organic solvent such as chloroform and cyclohexane and further freeze-drys, and then the resulting lipid mixture is dispersed in a solvent such as water and mixed with an aqueous solution of RNAi molecules. It is an object of the present invention to provide an industrial production method of lipoplex that does not require a complicated lipoplex production process, and easily produces a powder that easily produces lipoplex by suspending in a solvent such as water.
- the purpose is to eliminate the complicated and labor-intensive lipoplex dispensing process in the hospital pharmacy.
- the present inventors have dissolved dioleyl phosphatidylethanolamine (DOPE), phosphatidylcholine and cationic lipid in alcohol having high biotolerability and non-explosive properties, After dripping the alcohol solution into the RNAi molecule solution while stirring, the solution was freeze-dried, and a lyophilized product of lipoplex could be produced by removing a solvent such as alcohol. And the lyophilized product of the lipoplex obtained by this method can be mixed with an appropriate buffer solution and administered locally to the target organ affected with cancer, thereby effectively treating the cancer patient. I found. The present invention is based on these findings.
- DOPE dioleyl phosphatidylethanolamine
- the present invention is as follows. [1] A method for producing a lipoplex comprising dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine and a cationic lipid, and an RNAi molecule, (A) dissolving dioleoylphosphatidylethanolamine (DOPE), phosphatidylcholine and cationic lipid in alcohol; (B) a step of dropping the alcohol solution obtained in (a) under stirring into a solution in which RNAi molecules are dissolved, and (c) a step of freeze-drying the solution obtained in (b).
- DOPE dioleylphosphatidylethanolamine
- DOPE dioleylphosphatidylethanolamine
- phosphatidylcholine phosphatidylcholine and cationic lipid
- RNAi molecule an RNAi molecule
- the phosphatidylcholine has one or more characteristics selected from the following (i)-(iii): (I) containing at least one unsaturated fatty chain containing a carbon-carbon double bond; (Ii) at least one unsaturated fatty chain containing a cis-type carbon-carbon double bond; (Iii) a phase transition temperature of less than 0 ° C.
- the above method [2] The method according to [1], wherein the cationic lipid is O, O′-ditetradecanoyl-N- ( ⁇ -trimethylammonioacetyl) diethanolamine chloride (DC-6-14).
- the phosphatidylcholine is 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), palmitoyl oil phosphatidylcholine (POPC), or 1,2-diecosenoyl-sn-glycero-3-phosphocholine (DEPC).
- DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
- POPC palmitoyl oil phosphatidylcholine
- DEPC 1,2-diecosenoyl-sn-glycero-3-phosphocholine
- a lipid mixture comprising dioleyl phosphatidylethanolamine (DOPE), phosphatidylcholine and a cationic lipid, wherein the phosphatidylcholine has one or more characteristics selected from the following (i)-(iii): (I) containing at least one unsaturated fatty chain containing a carbon-carbon double bond; (Ii) at least one unsaturated fatty chain containing a cis-type carbon-carbon double bond; (Iii) peritoneal dissemination of gastric cancer, ovarian cancer, and pancreatic cancer, comprising a phase transition temperature of less than 0 ° C.
- DOPE dioleyl phosphatidylethanolamine
- phosphatidylcholine has one or more characteristics selected from the following (i)-(iii): (I) containing at least one unsaturated fatty chain containing a carbon-carbon double bond; (Ii) at least one unsaturated fatty chain containing a cis-type
- TS-shRNA short hairpin RNA
- a pharmaceutical composition for topical administration for treating metastasis [8] The pharmaceutical composition according to [7], wherein the cationic lipid is O, O′-ditetradecanoyl-N- ( ⁇ -trimethylammonioacetyl) diethanolamine chloride (DC-6-14).
- the pharmaceutical composition according to [7], wherein the lipid mixture comprises DOPE, DOPC and DC-6-14.
- cancer chemotherapeutic agent is selected from the group consisting of an antitumor agent having a microtubule depolymerization inhibitory action, a deoxycytidine derivative, and an antitumor agent having a TS inhibitory action.
- a large amount of an organic solvent such as chloroform or cyclohexane is used, and after further freeze-drying, the resulting lipid mixture is dispersed in a solvent such as water and mixed with an aqueous solution of RNAi molecules or the like. It is possible to provide an industrial method for producing a lipoplex that does not require a complicated lipoplex production process and can easily produce a powder that easily forms a lipoplex simply by suspending in a solvent such as water.
- RNAi molecules capable of suppressing tumor growth can be efficiently delivered to tumor cells.
- FIG. 1 was obtained by dissolving a lipid mixture composed of DOPC, DOPE and DC-6-14 obtained by a conventionally known method in an organic solvent (cyclohexane / ethanol (95/5 (V / V))).
- a formulation prepared by lyophilizing a solution and dispersing the obtained dried product in water and mixing an aqueous solution of RNAi molecules (conventional formulation), and DOPC obtained by the method of the present invention , DOPE and DC-6-14 were dissolved in an organic solvent (cyclohexane / ethanol (95/5 (V / V))), the resulting solution was lyophilized, and the resulting dried product was A solution prepared by uniformly dissolving in ethanol and then plucked into a homogeneous aqueous solution of RNAi molecules while stirring, freeze-drying the resulting solution, and dispersing the resulting dried product in water (new) Formulation (1)) Then, a homogeneous solution in which each lipid of DOPC, DOPE, and DC-6
- FIG. 2 is a photographic diagram showing the results of comparison of TS-shRNA retention ability between a conventional preparation obtained by a conventionally known method and a new preparation (1) and a new preparation (2) obtained by the method of the present invention.
- FIG. 3 shows tumors obtained by intraperitoneal administration of a conventional preparation obtained by a conventionally known technique, a novel preparation (1) obtained by the method of the present invention, and a novel preparation (2) to a peritoneal dissemination metastasis model mouse of gastric cancer.
- FIG. 4 shows the luciferase activity (ie, tumor growth inhibitory effect) in the group in which the conventional preparation, the new preparation (1) and the new preparation (2) were respectively administered into the abdominal cavity of a peritoneal dissemination model mouse of gastric cancer and the target group. It is the graph figure which quantified. ***: P ⁇ 0.005 FIG.
- FIG. 5-1 shows the administration of lipoplex carrying TS-shRNA (new preparation (2)) alone, administration of paclitaxel alone, and lipoplex carrying TS-shRNA (new preparation (2)) and paclitaxel. It is a photograph figure which shows the analysis result by IVIS of the growth inhibitory effect of the tumor with respect to the peritoneum dissemination metastasis
- FIG. 5-2 is a graph showing the results of quantifying tumor growth in the abdominal cavity based on the imaging data of FIG. 5-1.
- FIG. 5-3 shows the results shown in FIG. 5-2 in a logarithmic graph.
- FIG. 5-4 shows the subject group, the lipoplex carrying the TS-shRNA (new preparation (2)) alone, the paclitaxel alone group, and the TS- in the animal experiment shown in FIG. It is the graph which showed the life prolonging effect between the combined administration groups with the lipoplex (New formulation (2)) which carries shRNA.
- Fig. 5-5 shows changes in TS-shRNA concentration in ascites and blood after intraperitoneal administration of lipoplexes carrying the TS-shRNA (new formulation (2)) to peritoneal dissemination metastasis model mice of ovarian cancer Is a graph showing the results of measurement by RT-PCR.
- FIG. 6-2 shows the results shown in FIG. 6-1 in a logarithmic graph.
- FIG. 6-3 shows that a lipoplex carrying TS-shRNA (new formulation (2)) alone, paclitaxel alone, and a lipoplex carrying TS-shRNA (new formulation (2)) and paclitaxel. It is the graph which showed the life extension effect among the peritoneum dissemination metastasis
- the lipoplex of the present invention is a complex comprising or consisting of a lipid mixture comprising dioleyl phosphatidylethanolamine (DOPE), phosphatidylcholine and a cationic lipid and an RNAi molecule.
- DOPE dioleyl phosphatidylethanolamine
- the “phosphatidylcholine” usable in the present invention has one or more characteristics selected from the following (i)-(iii): (I) containing at least one unsaturated fatty chain containing a carbon-carbon double bond; (Ii) containing at least one unsaturated fatty chain containing a cis-type carbon-carbon double bond; (Iii) Low phase transition temperature (for example, less than 0 ° C, less than -10 ° C, less than -20 ° C).
- phosphatidylcholine examples include 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), palmitoyl oil phosphatidylcholine (POPC), 1,2-diecosenoyl-sn-glycero-3-phosphocholine (DEPC). Is mentioned. DOPC is preferable.
- Examples of the “cationic lipid” that can be used in the present invention include O, O′-ditetradecanoyl-N- ( ⁇ -trimethylammonioacetyl) diethanolamine chloride (DC-6-14), N, N-dioleyl- N, N-dimethylammonium chloride (DODAC), N, N-distearyl-N, N-dimethylammonium bromide (DDAB), N- (1- (2,3-dioleoyloxy) propyl) -N, N , N-trimethylammonium chloride (DOTAP), N- (1- (2,3-dioleyloxy) propyl) -N, N, N-trimethylammonium chloride (DOTMA), N, N-dimethyl- (2,3 -Utilizing any one selected from dioleyloxy) propylamine (DODMA) and derivatives thereof Rukoto can.
- the cationic lipid is DC-6-14.
- the lipoplex in the present invention contains a lipid mixture consisting of DOPE, DOPC and DC-6-14.
- DOPE: DOPC: DC-6-14 3: 2: 5.
- the lipoplex of the present invention has a particle size of 200 nm to 2000 nm, preferably about 400 nm to 700 nm.
- the zeta potential of the lipoplex of the present invention is 30 to 60 mV, preferably about 30 to 40 mV.
- the lipoplex of the present invention can be produced by a technique including the following steps.
- a lyophilized product of a mixture of phosphatidylethanolamine, phosphatidylcholine and cationic lipid, or each component is dissolved in alcohol.
- ethanol or methanol can be used, and ethanol having high biotolerability is particularly preferable.
- Phosphatidylethanolamine, phosphatidylcholine and cationic lipid can be used in any form, for example, powders can be used.
- Phosphatidylethanolamine, phosphatidylcholine and cationic lipid may be separately dissolved in alcohol separately, and then separated and mixed so as to be the predetermined amount, or phosphatidylethanolamine which is the predetermined amount,
- a lyophilized product of a lipid mixture composed of phosphatidylcholine and a cationic lipid may be dissolved in alcohol.
- phosphatidylethanolamine, phosphatidylcholine and cationic lipid can be independently contained at 1 to 100 mM, preferably 10 to 80 mM.
- the dissolution of phosphatidylethanolamine, phosphatidylcholine and cationic lipid in alcohol can be performed by heating. For example, it can be carried out by heating to 35 ° C. to 60 ° C., preferably 40 ° C. to 50 ° C.
- the obtained alcohol solution is dropped into a solution in which RNAi molecules are dissolved (for example, an aqueous solution in water) with stirring, and the resulting solution is lyophilized to obtain a lyophilized lipoplex.
- a solution in which RNAi molecules are dissolved for example, an aqueous solution in water
- the alcohol solution and the solution in which RNAi molecules are dissolved are preferably mixed at a ratio of 1 to 3: 7 to 9.
- the obtained lyophilized product can be further mixed with an aqueous solution such as a buffer solution to obtain a lipoplex suspension, which can be administered to a living body.
- the buffer solution may be an aqueous solution that can be administered to a living body, and for example, physiological saline, saccharide infusion, or the like can be used.
- Mixing is preferably carried out with a vortex mixer or the like for 1 to 15 minutes, preferably about 5 minutes. By adding the stirring, the particle size of the lipoplex can be adjusted to the desired size.
- the lipoplex production method of the present invention is highly toxic and does not require the use of highly explosive chloroform or cyclohexane, so there is no need to provide heavy equipment for explosion protection in the production plant of the preparation, Even if there is a very small amount of residual solvent, it is only ethanol with high biotolerability, and there are few problems in administration to patients.
- lipoplexes at medical sites such as hospital dispensing departments.
- a vial for injection filled with the lyophilized product of the above-mentioned lipoplex to the medical site, it is possible to include the lipoplex just by adding a buffer solution to the dispensing department of the hospital before administration to the patient.
- An administration liquid aqueous dispersion
- the lipoplex of the present invention can be used for local administration to a patient.
- “local administration” is not intended for systemic administration such as intravenous injection.
- Examples of the topical administration include intraperitoneal, intrathoracic, intramuscular, subcutaneous, intradermal, intraocular, intracerebral, intracerebral spinal cavity, intravaginal, intrarectal, internal organ, and application to the epidermis.
- Topical administration is preferably intracavitary administration, more preferably intrathoracic administration or intraperitoneal administration.
- the lipoplex of the present invention contains, as an active ingredient, an RNAi molecule (such as siRNA or shRNA) that is capable of suppressing the expression of a gene that is expressed in tumor cells and that encodes a factor involved in the growth of tumor cells by RNAi action.
- an RNAi molecule such as siRNA or shRNA
- RNAi action Including.
- Examples of “genes encoding factors that are expressed in tumor cells and are involved in the growth of tumor cells” include, for example, growth regulators such as thymidylate synthase, VEGF, EGFR, PDGF, HGF, Wint, Bcl-2, survivin
- genes encoding nucleic acid synthesis-related enzymes such as ribonucleotide reductase and DNA polymerase, but are not limited thereto.
- genes are disclosed in known databases such as GenBank, and siRNA or shRNA can be designed and synthesized based on these gene information.
- shRNA capable of suppressing the expression of thymidylate synthase by RNAi action, those described in detail below can be used.
- a cancer chemotherapeutic agent can also be used as an active ingredient.
- the RNAi molecule may be contained in a hollow part surrounded by the lipid bilayer membrane of the lipid mixture, or may be bound to the outer membrane surface of the lipid bilayer membrane. Bonded to the outer membrane surface of the bilayer. The binding of the RNAi molecule to the outer membrane surface of the lipid bilayer membrane can be achieved by the above production method.
- the lipoplex of the present invention can be used as an antitumor agent.
- the lipoplex of the present invention contains shRNA that can suppress the expression of thymidylate synthase (hereinafter referred to as “TS”) by RNAi action.
- TS thymidylate synthase
- the shRNA capable of suppressing the expression of TS in the present invention can exhibit the RNAi action specifically for TS by targeting the mRNA of TS, and can remarkably suppress the expression of TS.
- targeting mRNA means that the antisense strand of shRNA described in detail below can hybridize with the target mRNA under stringent conditions.
- the stringent condition can be determined based on the melting temperature (Tm) of the nucleic acid that forms a hybrid according to a conventional method. For example, as washing conditions that can maintain the hybridized state, it is usually about “1 ⁇ SSC, 0.1% SDS, 37 ° C.”, more strictly “0.5 ⁇ SSC, 0.1% SDS, 42 ° C.” More specifically, a condition of “0.1 ⁇ SSC, 0.1% SDS, 65 ° C.” can be mentioned.
- ShRNA in the present invention includes a sense strand having the same base sequence as the ORF base sequence encoding TS or a part thereof, and an antisense strand that hybridizes with the sense strand under stringent conditions.
- the “base sequence identical to the ORF base sequence or a part thereof” means a base sequence identical to the base sequence represented by substituting uracil for thymine in the base sequence of the ORF or a part thereof. To do.
- the sense strand consists of 15 to 25 bases, preferably 19 bases.
- the base sequence of the sense strand is preferably the same as the base sequence of the ORF encoding TS, but it may be substantially the same, that is, a homologous sequence.
- the base sequence of the sense strand is one or more in the base sequence of ORF, that is, 1 to 3 bases, preferably 1 to 2 bases, more preferably 1 base substitution, deletion, insertion and / or addition. There may be.
- the antisense strand has a base sequence that can hybridize with the sense strand under stringent conditions.
- the antisense strand has a mismatch including substitution, deletion, insertion and / or addition of 1 to 3 bases, preferably 1 to 2 bases, more preferably 1 base as long as it can hybridize under stringent conditions It may be a thing.
- the antisense strand consists of a base sequence that is completely complementary to the sense strand.
- the base sequence of the sense strand and antisense can be selected based on a known base sequence (GenBank: CR601528.1) encoding TS. Various methods are known as a method for selecting these base sequences. For example, siRNA Design Support System (Takara Bio Inc.) can be used.
- the sense strand includes, but is not limited to, those consisting of the following base sequences: 5′-GUAACACCCAUCGAUCAUGA-3 ′ (SEQ ID NO: 1); 5′-GAAUACAGAGAUAUUGGAAU-3 ′ (SEQ ID NO: 3); '-CGAUCAUGAUGUAGAGGUGU-3' (SEQ ID NO: 5).
- the shRNA in the present invention comprises sense strand 5′-GUAACACCCAUCGAUCAUGA-3 ′ (SEQ ID NO: 1) and antisense strand 5′-UCAUGAUCGAUGGUGUUAC-3 ′ (SEQ ID NO: 2); sense strand 5′-GAAUACAGAGAUAUGAGAAU-3 ′ (sequence No. 3) and antisense strand 5′-AUUCCCAUAUCUCUGUAUUCUC-3 ′ (SEQ ID NO: 4); or sense strand 5′-CGAUCAUGAUGUAGAUGU-3 ′ (SEQ ID NO: 5) and antisense strand 5′-ACACUCUACAUCAUGAUCG-3 ′ (SEQ ID NO: 6) )including.
- the shRNA in the present invention comprises a sense strand consisting of the base sequence represented by SEQ ID NO: 1 and an antisense strand consisting of the base sequence represented by SEQ ID NO: 2.
- the sense strand and the antisense strand are connected via a linker portion, the linker portion is folded by forming a loop, and the antisense strand and the sense strand are hybridized to form a double-stranded portion.
- the linker part contained in the shRNA molecule may be a polynucleotide linker or a non-polynucleotide linker as long as it can link the sense strand and the antisense strand to form a stem loop structure, and is not particularly limited. Polynucleotide linkers of 2 to 22 bases known to those skilled in the art are preferred.
- UAGUGCUCCUGGUUG SEQ ID NO: 7
- UUCAAGGAGA CCACC
- CUCGAG CUCGAG
- CCACACC UUCAGAGAGA
- AUG, CCC and UUCG can be exemplified
- UAGUGCUCCUGGUUG SEQ ID NO: 7
- ShRNA in the present invention has an overhang consisting of at least 2 bases at the 3 'end.
- the overhang refers to a base added to the 3 'end of the antisense strand and having no base capable of complementary binding at the corresponding position of the sense strand.
- the degree of suppression of TS expression by shRNA is reduced by about 40 to 60% compared to the case where it has an overhang.
- the type and number of bases of the overhang are not limited, and examples include sequences consisting of 1 to 5, preferably 1 to 3, more preferably 1 or 2 bases, such as TTT, UU, and TT. . Preferably, it is UU.
- a preferred shRNA is a single-stranded RNA consisting of the base sequence represented by SEQ ID NO: 8.
- sense strand or the antisense strand may be phosphorylated at the 5 'end as necessary, or triphosphate (ppp) may be bound to the 5' end.
- ppp triphosphate
- the lipoplex provided with shRNA in the present invention has an RNAi effect on the expression of “a gene encoding a factor that is expressed in tumor cells and involved in the growth of tumor cells”. It may contain siRNA or shRNA that can be suppressed by. As such siRNA or shRNA, those defined above can be used.
- the shRNA that can suppress the expression of TS and other siRNA or shRNA may be present on the same lipoplex, or may be present on separate lipoplexes.
- lipoplexes with the above-mentioned shRNA by local administration can suppress the growth of tumor cells and can be used for treating cancer.
- cancers that can be treated using the antitumor agent of the present invention include cancers that highly express TS, and are not particularly limited. Examples thereof include colon and rectal cancers, liver cancers, kidney cancers, head and neck cancers. Cancer, esophageal cancer, stomach cancer, biliary tract cancer, gallbladder / bile duct cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, prostate cancer, malignant pleural mesothelioma, testicular tumor, ovary Examples include cancer, bone / soft tissue sarcoma, skin cancer, brain tumor and the like.
- Cancerous pleurisy and cancerous peritonitis can also be treated with the antitumor agent.
- Treatment candidates are preferably gastric cancer, lung cancer, biliary tract cancer, liver cancer, malignant pleural mesothelioma, ovarian cancer, cancerous pleurisy and peritonitis, particularly preferably gastric cancer, ovarian cancer and pancreatic cancer peritoneal dissemination metastasis, pleural malignancy Mesothelioma, lung cancer and cancerous pneumonia with main lesion in the thoracic cavity.
- the antitumor agent of the present invention is also commonly used in the manufacture of pharmaceuticals together with lipoplexes, such as excipients, binders, disintegrants, lubricants, diluents, solubilizers, suspending agents, etc. It may contain tonicity agents, pH adjusters, buffers, stabilizers, colorants, flavoring agents, flavoring agents, histidine and the like.
- excipient examples include lactose, sucrose, sodium chloride, glucose, maltose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silica
- examples include acid, methylcellulose, glycerin, sodium alginate, gum arabic, and mixtures thereof.
- lubricant examples include purified talc, stearate, borax, polyethylene glycol, and a mixture thereof.
- binder examples include simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, carboxymethyl cellulose, shellac, methyl cellulose, ethyl cellulose, water, ethanol, potassium phosphate, and a mixture thereof.
- disintegrant examples include dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and mixtures thereof. Is mentioned.
- Examples of the diluent include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and mixtures thereof.
- Examples of the stabilizer include sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, and a mixture thereof.
- Examples of the isotonic agent include sodium chloride, boric acid, glucose, glycerin and a mixture thereof.
- Examples of the pH adjuster and buffer include sodium citrate, citric acid, sodium acetate, sodium phosphate, and mixtures thereof.
- the antitumor agent of the present invention can be administered by local administration. Topical administration includes those defined above.
- the composition of the present invention can be made into a dosage form suitable for topical administration, and can be prepared in various preparation forms such as injections, suspensions, emulsifiers and sprays.
- the antitumor agent of the present invention can be provided in a lyophilized form, and can be used after adding an appropriate buffer (for example, physiological saline).
- the effect of the antitumor agent of the present invention is that the antitumor agent is administered to cells and tissues derived from the cancer and the individual suffering from the cancer, and the tumor size is not administered to the antitumor agent ( Alternatively, it can be evaluated by using as an index that the tumor is shrinking or disappearing as compared with the size of the tumor in the cells and tissues and the individual before administration. Further, the effect of the antitumor agent of the present invention is that the antitumor agent is administered to cells and tissues derived from the cancer, and the individual suffering from the cancer, and compared to an individual who is not administered the antitumor agent. Thus, it is possible to evaluate by using as an index the improvement of survival rate (life extension effect) and the decrease or disappearance of pleural effusion or ascites.
- the antitumor agent of the present invention can be used together with existing cancer chemotherapy and cancer chemotherapeutic agents.
- the cancer chemotherapy or cancer chemotherapeutic agent that can be used in combination with the antitumor agent of the present invention may be any one that can modify the tumor environment so that the lipoplex of the present invention can easily enter the tumor tissue.
- Taxol registered trademark
- Taxotere registered trademark
- Sanofiaventis As a cancer chemotherapeutic agent, depolymerization of microtubules such as Taxol (registered trademark) (Bristol-Meier Squibb) and Taxotere (registered trademark) (Sanofiaventis), which are effective in patients with peritoneal dissemination metastasis of gastric cancer and ovarian cancer
- Antitumor agents having an inhibitory action, and antitumor agents comprising deoxycytidine derivatives such as gemcitabine (registered trademark) (Eli Lilly) useful for the treatment of pancreatic cancer and peritoneal dissemination metastasis.
- the antitumor agent of the present invention can be used together with other existing cancer chemotherapeutic agents in addition to or in place of the above cancer chemotherapeutic agents.
- cancer chemotherapeutic agents include cyclophosphamide, nitrogen mustard N-oxide, ifosfamide, melphalan, busulfan, mitobronitol, carbocon, thiotepa, ranimustine, nimustine, temozolomide, carmustine, pemetrex dosodymium, methotrexate, And 6-mercaptopurine riboside, mercaptopurine, doxyfluridine, carmofur, cytarabine, cytarabine ocphosphate, enositabine, fludarabine, pemetrexed, cisplatin, carboplatin, oxaliplatin, docetaxel, irinotecan hydrochloride, capecitabine, etc.
- cancer chemotherapeutic agents can be used. Similar to the above cancer chemotherapeutic agents, these cancer chemotherapeutic agents can also deliver shRNA efficiently to tumor cells in combination with the antitumor agent of the present invention. Compared with the case where the antitumor agent of the invention is used alone, a significantly higher antitumor effect can be obtained.
- the antitumor agent of the present invention and the existing cancer chemotherapeutic agent are administered in combination, they can be provided as a combination.
- the antitumor agent of the present invention can be in the form of a “combination” together with the above existing cancer chemotherapeutic agents.
- the “combination” may be a combination drug containing the antitumor agent of the present invention and the above existing cancer chemotherapeutic agent as active ingredients, and the antitumor agent of the present invention and the above existing cancer chemotherapeutic agent. May be manufactured, packaged and distributed as a single package (kit formulation) suitable for combined administration.
- the antitumor agent of the present invention and the existing cancer chemotherapeutic agent are administered simultaneously, but also the antitumor agent of the present invention and the existing cancer chemotherapeutic agent are spaced apart. Administration is also included.
- the administration route and administration means of the antitumor agent of the present invention and the existing cancer chemotherapeutic agent may be the same or different.
- the dose and frequency of administration of the antitumor agent of the present invention may vary depending on factors such as the patient's age, weight, disease severity, etc., but the amount of shRNA is 0.0001 mg to 100 mg per kg body weight at a time. An amount appropriately selected from these ranges can be administered 1 to 3 times a day, every day, or every 1 to 21 days.
- the dose of the above existing cancer chemotherapeutic agent may vary depending on factors such as the type of chemical substance that is an active ingredient, the age, weight of the patient, severity of the disease, etc., but 0.0001 mg per kg of body weight per time
- An amount appropriately selected from the range of ⁇ 1000 mg can be administered 1 to 3 times a day, every day or every 1 to 14 days.
- the existing cancer chemotherapeutic agent is paclitaxel
- 500 to 1000 mg per day can be administered intraperitoneally or intravenously every 1 to 21 days.
- the existing chemotherapeutic agent is pemetrexed sodium hydrate
- 500-1000 mg per day can be administered intravenously every 1-21 days.
- the existing chemotherapeutic agent When the existing chemotherapeutic agent is TS-1 of 5-FU oral anticancer agent, it can be administered 1 to 3 times a day, every day or every 2 to 3 days.
- the existing cancer chemotherapeutic agent can be administered at a lower dose and more frequently than when used alone.
- cancer chemotherapeutic agents for example, myelosuppression, hemolytic anemia, disseminated intravascular coagulation syndrome, fulminant hepatitis, dehydration, enteritis, interstitial pneumonia, stomatitis, Gastrointestinal ulcer, gastrointestinal hemorrhage, gastrointestinal perforation, acute renal failure, mucocutaneous ocular syndrome, toxic epidermal necrosis, neuropsychiatric disorder, acute pancreatitis, rhabdomyolysis, loss of olfactory, etc.
- myelosuppression hemolytic anemia, disseminated intravascular coagulation syndrome, fulminant hepatitis, dehydration, enteritis, interstitial pneumonia, stomatitis, Gastrointestinal ulcer, gastrointestinal hemorrhage, gastrointestinal perforation, acute renal failure, mucocutaneous ocular syndrome, toxic epidermal necrosis, neuropsychiatric disorder, acute pancreatitis, rhabdomyolysis, loss of
- the present invention also relates to a method for treating cancer using the antitumor agent of the present invention.
- Cancers that can be treated by the method include cancers as defined above.
- the usage and dosage of the antitumor agent of the present invention and the existing cancer chemotherapeutic agent are as described above.
- Example 1 Preparation of lipoplex
- DOPE Dioleylphosphatidylethanolamine
- DOPC Nippon Seiken 1,2-dioleoyl-sn-glycero-3-phosphocholine
- DC-6-14 Pharmaron Ethanol: Wako Pure Chemical Industries Sodium chloride: Wako Pure Chemical Industries
- ShRNA targeting TS (hereinafter referred to as “TS-shRNA”) is a known shRNA that can suppress TS expression and has been confirmed to have an antitumor effect (see WO2012 / 161196). Based on the above, one having the following sequence was synthesized.
- TS-shRNA aqueous solution 3.8 ⁇ L of 300 ⁇ M TS-shRNA was added to RNase free water (66.2 ⁇ L) to obtain a TS-shRNA aqueous solution.
- the lipid mixture ethanol solution (30 ⁇ L) was gradually added dropwise to the TS-shRNA aqueous solution (70 ⁇ L) to obtain a lipoplex ethanol / water solution.
- the obtained lipoplex ethanol / water solution was frozen at ⁇ 40 ° C. or lower and then freeze-dried using a vacuum freeze dryer (LABCONCO FZ-4.5, Asahi Life Science).
- new preparation (1) the lipoplex thus obtained is referred to as “new preparation (1)”.
- the obtained lipoplex ethanol / water solution was freeze-dried in the same manner as in (1-1) above, and the physiological saline prepared with RNase free water was added and stirred to obtain the lipoplex (TS-shRNA amount). 20 ⁇ g / 100 ⁇ L) was obtained.
- new preparation (2) the lipoplex thus obtained is referred to as “new preparation (2)”.
- Example 2 Equivalent comparison of physical properties of each lipoplex Using Zetasizer Nano ZS (Malvern), the particle size (d) of the new formulation (1), the new formulation (2) and the conventional formulation obtained in Example 1 .Nm), polydispersity index (PdI), and zeta potential (mV).
- Example 3 Evaluation of lipoplex TS-shRNA retention ability
- Tris Wako Pure Chemical Industries Boric Acid: Wako Pure Chemical Industries
- EDTA 2Na Sigma-Aldrich Agarose: Sigma-Aldrich
- Tris (5.4 g), boric acid (2.75 g), and EDTA ⁇ 2Na (0.185 g) were weighed, and made up to 1 L with distilled water to prepare a TBE buffer solution.
- TBE buffer 40 mL
- agarose 0.4 g
- EtBr 4 ⁇ L
- pour it into a gel plate and return to room temperature to 1 % Agarose gel was prepared.
- Example 4 Evaluation of target gene suppression effect in tumor by intraperitoneal administration of each lipoplex (real-time RT-PCR)
- the reagents described below were used.
- Reverse primer for TS mRNA Life Technologies Base sequence: 5′-AGG AGT TGC TGT GGT TTA TCA AG-3 ′ (SEQ ID NO: 10)
- Forward primer for GAPDH mRNA Life Technologies Base sequence: 5′-CTC TGC TCC TCC TGT TCG AC-3 ′ (SEQ ID NO: 11)
- MKN45 human gastric cancer cells were cultured and transplanted into the abdominal cavity of BALB / c nu / nu mice (5 weeks old, male) at 5 ⁇ 10 6 cells / mouse.
- the body weights of mice on the day of transplantation and 6 days after transplantation were measured, and mice whose body weight was decreased (it is considered that transplanted cells were engrafted) were subjected to experiments as MKN45 peritoneal seeding model mice.
- TS-shRNA 20 ⁇ g / mouse / day.
- MULTI-BEADS SHOCKER registered trademark
- RNA was extracted using RNeasy (registered trademark) Mini Kit (QIAGEN).
- RNA concentration of the obtained RNA extract was diluted with RNase free water so that the RNA concentration would be 1 ⁇ g / 7.7 ⁇ L, and TaqMan (registered trademark) Reverse TransferReciptions was used. Reverse transcription was performed (16 ° C for 30 minutes, 42 ° C for 30 minutes, 85 ° C for 5 minutes).
- TS mRNA amount and GAPDH mRNA amount were measured by carrying out 40 cycles of 10 minutes at 95 ° C for 15 seconds; 60 ° C for 1 minute.
- FIG. 3 shows a model mouse (TS mRNA expression level) obtained by correcting TS mRNA values measured by real-time RT-PCR with GAPDH mRNA values. The value is shown as a relative value with the value of the control group being 100%.
- Example 5 Evaluation of target gene suppression effect in tumor by intraperitoneal administration of each lipoplex (In Vivo Imaging Systems: IVIS)
- Luciferin Wako Pure Chemical Industries
- PBS Nissui Pharmaceutical
- Luc-shRNA shRNA targeting luciferase (Luc)
- the shRNA targeting Luc has the following sequence.
- luciferase luciferase (Luc-shRNA) was used to carry Luc-shRNA in the same manner as the lipoplex preparation method described in Example 1 except that shRNA was replaced with Luc-shRNA. Lipoplexes were prepared, and the target gene-suppressing effect on tumors of the new preparation (1), the new preparation (2) and the conventional preparation was evaluated by IVIS.
- NCI-N87 human gastric cancer cells (NCI-N87-Luc, Sumisho Pharma International) are cultured and 4 ⁇ 10 6 cells (cells) in the peritoneal cavity of BALB / c nu / nu mice (5 weeks old, male, Japan SLC) NCI-N87-Luc peritoneal seeding model mice were prepared by transplanting to become mice.
- Luc-shRNA 20 days after cell transplantation
- the conventional preparation, the new preparation (1), or the new preparation (2) were added at a dose of Luc-shRNA of 20 ⁇ g / mouse / day.
- Each model mouse was intraperitoneally administered so that In addition, luciferin was dissolved in PBS to 7.5 mg / mL, and 10 ⁇ L of luciferin was intraperitoneally administered on the 7th, 10th, 13th, 16th, 19th, and 22nd days after cell transplantation. The luciferase activity was observed with IVIS (Xenogen, Alameda, CA, USA). A model mouse to which 9% sucrose solution was administered without administration of lipoplex was used as a control group.
- Fig. 4 shows a graph (Fig. 4) in which luciferase activity in the abdominal cavity is quantified using the obtained imaging data.
- the luciferase activity increased with time, indicating that the tumor was growing in the abdominal cavity.
- the new preparation (1) and the new preparation (2) a marked decrease in luciferase activity was observed after the first administration, and experiments were conducted. Luciferase activity did not rise again during the period (up to 22 days after cell transplantation) (FIG. 4).
- Luc-shRNA for luciferase was used, but it is unlikely that this will affect tumor growth. Actually, when the tumor weight of each group at 24 days after cell transplantation was measured, no significant difference was observed between the groups. From this, it was shown that administration of each lipoplex carrying Luc-shRNA suppressed only the activity of tumor luciferase. From these results, it was revealed that the same TS-shRNA activity was maintained between the lipoplex obtained by a conventionally known method and the novel lipoplex obtained by the method of the present invention.
- Example 6 Treatment evaluation for peritoneal dissemination of ovarian cancer by intraperitoneal administration of lipoplex (new formulation (2)) Lipoplex carrying TS-shRNA (new formulation (2)) prepared in the same manner as in Example 1 above ) was evaluated for therapeutic effect on peritoneal dissemination of ovarian cancer.
- Luciferase-expressing OVCAR-3 human ovarian cancer cells (OVCAR-3-luc, Pharmaron) were cultured and BALB / c nu / nu mice (6-8 weeks old, female, Beijing HFK Bio-Technology Co., LTD).
- OVCAR-3-luc peritoneal dissemination model mice were prepared by transplanting into the peritoneal cavity at 1.5 ⁇ 10 7 cells / mouse.
- model mice were administered lipoplex (new formulation (2)), paclitaxel (taxol, Pharmalon), lipoplex (new formulation (2)) and paclitaxel.
- the control received a 9% sucrose solution.
- Luciferin was dissolved in PBS to 7.5 mg / mL, and 10 ⁇ L of luciferin was intraperitoneally administered on the 7th, 14th, 21st, and 26th days after cell transplantation, and then the luciferase activity of the tumor was observed by IVIS .
- FIG. 5-1 The results are shown in Figure 5-1.
- a graph quantifying luciferase activity in the abdominal cavity using the imaging data of FIG. 5-1 (FIG. 5-2) and its logarithmic graph (FIG. 5-3) are shown.
- the luciferase activity increased with time, indicating that the tumor was growing in the abdominal cavity.
- the increase in luciferase activity was suppressed in the group in which the lipoplex carrying TS-shRNA was intraperitoneally administered compared to the control group, that is, the tumor growth in the abdominal cavity was suppressed. It was. Furthermore, the highest tumor suppressive effect was observed in the group using lipoplex and paclitaxel in combination.
- Example 7 Treatment evaluation for peritoneal dissemination of pancreatic cancer by intraperitoneal administration of lipoplex (new formulation (2)) Lipoplex carrying TS-shRNA (new formulation (2)) prepared in the same manner as in Example 1 above The therapeutic effect on peritoneal dissemination of pancreatic cancer was evaluated.
- Luciferase-expressing PANC-1 human pancreatic cancer cells (PANC-1-luc, Pharmalon) were cultured and peritoneal cavity of BALB / c nu / nu mice (6-8 weeks old, female, Beijing HFK Bio-Technology Co., LTD).
- a PANC-1-luc peritoneal seeding model mouse was prepared by transplanting the cells into 1.0 ⁇ 10 7 cells / mouse.
- model mice were administered lipoplex (new formulation (2)), paclitaxel (taxol, Pharmalon), lipoplex (new formulation (2)) and paclitaxel.
- the control received a 9% sucrose solution.
- Luciferin was dissolved in PBS to 7.5 mg / mL, and 10 ⁇ L of luciferin was intraperitoneally administered on the 7th, 14th, 21st, and 25th days after cell transplantation, and then the luciferase activity of the tumor was observed by IVIS .
- Fig. 6 shows a graph quantifying luciferase activity in the abdominal cavity based on the IVIS imaging data (Fig. 6-1) and its logarithmic graph (Fig. 6-2).
- the luciferase activity increased with time, indicating that the tumor was growing in the abdominal cavity.
- the increase in luciferase activity was suppressed compared to the control group. That is, it was confirmed that tumor growth in the abdominal cavity was suppressed.
- a high tumor suppressing effect was observed in the group administered with paclitaxel and the group combined with lipoplex and paclitaxel.
- a lipoplex using only a highly biologically acceptable solvent without using an organic solvent that is highly toxic and has a high risk of explosion, such as chloroform and cyclohexane. It is ideal for industrial production of pharmaceutical preparations. Also, in the medical field such as the pharmacy department of hospitals, an aqueous dispersion of a lipid mixture and an aqueous solution of RNAi molecules are prepared, and complicated preparations for mixing the two can be avoided. In addition, since a liquid for administration to a patient can be prepared simply by stirring lightly, the labor and cost for dispensing in the pharmacy department of a hospital can be greatly reduced.
- RNAi molecules can be efficiently delivered to tumor cells by performing appropriate local administration, such as intrathoracic administration, and efficient growth of the tumor. Can be suppressed.
- the present invention is expected to contribute greatly in the field of drug delivery and in the field of cancer treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1] ジオレイルホスファチジルエタノールアミン(DOPE)、ホスファチジルコリン及びカチオン性脂質ならびにRNAi分子を含むリポプレックスの製造方法であって、
(a)ジオレイルホスファチジルエタノールアミン(DOPE)、ホスファチジルコリン及びカチオン性脂質をアルコール中に溶解する工程、
(b)RNAi分子を溶解した溶液に、撹拌下、(a)で得られたアルコール溶液を滴下する工程、及び
(c)(b)で得られた溶液を凍結乾燥する工程、
を含み、該ホスファチジルコリンが以下の(i)-(iii)より選択される一以上の特徴を有する:
(i)炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(ii)シス型の炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(iii)相転移温度が0℃未満、
上記方法。
[2] カチオン性脂質がO,O’-ジテトラデカノイル-N-(α-トリメチルアンモニオアセチル)ジエタノールアミンクロリド(DC-6-14)である、[1]の方法。
[3] ホスファチジルコリンが1,2-ジオレオイル-sn-グリセロ-3-ホスホコリン(DOPC)、パルミトイルオエオイルホスファチジルコリン(POPC)、又は1,2-ジエイコセノイル-sn-グリセロ-3-ホスホコリン(DEPC)である、[1]又は[2]の方法。
[4] ホスファチジルコリンがDOPCである、[3]の方法。
[5] 工程(a)において、DOPE、DOPC及びDC-6-14をアルコール中に溶解して混合することを含む、[1]の方法。
[6] (d)(c)で得られた凍結乾燥物を緩衝液中に混合する工程をさらに含む、[1]~[5]のいずれかの方法。
[7] ジオレイルホスファチジルエタノールアミン(DOPE)、ホスファチジルコリン及びカチオン性脂質からなり、該ホスファチジルコリンが以下の(i)-(iii)より選択される一以上の特徴を有する、脂質混合物:
(i)炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(ii)シス型の炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(iii)相転移温度が0℃未満、と
RNAi作用によりチミジル酸合成酵素の発現を抑制することができるショートヘアピンRNA(TS-shRNA)とを含む、胃癌、卵巣癌、及び膵臓癌の腹膜播種転移を治療するための局所投与用医薬組成物。
[8] カチオン性脂質がO,O’-ジテトラデカノイル-N-(α-トリメチルアンモニオアセチル)ジエタノールアミンクロリド(DC-6-14)である、[7]の医薬組成物。
[9] ホスファチジルコリンがDOPCである、[7]の医薬組成物。
[10] 脂質混合物がDOPE、DOPC及びDC-6-14からなる、[7]の医薬組成物。
[11] DOPE、DOPC及びDC-6-14が、3:2:5のモル比で含まれる、[10]の医薬組成物。
[12] shRNAが配列番号8で表される塩基配列からなる、[7]~[11]のいずれかの医薬組成物。
[13] 癌化学療法剤と併用される、[7]~[12]のいずれかの医薬組成物。
[14] [7]~[13]のいずれかの医薬組成物と癌化学療法剤とを含む、組み合わせ物。
[15] 癌化学療法剤が微小管の脱重合阻害作用を有する抗腫瘍剤、デオキシシチジン誘導体、及びTS阻害作用を有する抗腫瘍剤からなる群から選択される、[14]の組み合わせ物。
(i) 炭素-炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(ii) シス型の炭素-炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(iii) 相転移温度が低い(例えば、0℃未満、-10℃未満、-20℃未満)。
本実施例において、試薬は以下に記載するものを用いた。
ジオレイルホスファチジルエタノールアミン(DOPE):日本精化
1,2-ジオレオイル-sn-グリセロ-3-ホスホコリン(DOPC):日本精化
O,O’-ジテトラデカノイル-N-(α-トリメチルアンモニオアセチル)ジエタノールアミンクロリド(DC-6-14):Pharmaron
エタノール:和光純薬工業
塩化ナトリウム:和光純薬工業
TSを標的とするshRNA(以下、「TS-shRNA」と記載する)は、TSの発現を抑制することができ、かつ抗腫瘍効果が既に確認されている公知のshRNA(WO2012/161196を参照)に基づいて、以下の配列を有するものを合成した。
TS-shRNA:
5’-GUAACACCAUCGAUCAUGAUAGUGCUCCUGGUUGUCAUGAUCGAUGGUGUUACUU-3’(配列番号8)
(1-1)脂質混合物の凍結乾燥物からのリポプレックス(新規製剤(1))の調製
日本精化製プレソームDF1(DOPE/DOPC/DC-6-14を、3/2/5のモル比で含む脂質混合物)(100mg)を秤量し、室温にてエタノール1.842mLに溶かすことで脂質混合物のエタノール溶液を得た。
DOPE(55.8mg)、DOPC(78.6mg)、及びDC-6-14(66.0mg)の粉末をそれぞれ秤量し、エタノール1mLをそれぞれに添加した後、40℃に加温することで75mM DOPE、100mM DOPC、100mM DC-6-14の溶液を得た。
DOPE(0.51mg)、DOPC(0.36mg)、及びDC-6-14(0.76mg)の粉末をそれぞれ秤量し、シクロヘキサン/エタノール混液(95%/5%(V/V))1.0mL中で混合し、溶解した。次いで、得られた溶液を凍結乾燥処理してシクロヘキサン・エタノールを除去した後、生理食塩水(50μL)を加えて、ボルテックスミキサーを用いて10分間激しく撹拌し、懸濁させた後、TS-shRNAを含む(0.4μg/μL)水溶液(50μL)を入れて混合することによってリポプレックス(TS-shRNA量として20μg/100μL)を得た。
Zetasizer Nano ZS(Malvern)を用いて、実施例1で得られた新規製剤(1)、新規製剤(2)及び従来製剤の粒子径(d.nm)、多分散度指数(polydispersity index:PdI)、及びゼータ電位(mV)を測定した。
本実施例において、試薬は以下に記載するものを用いた。
Tris:和光純薬工業
ホウ酸:和光純薬工業
EDTA・2Na:Sigma-Aldrich
アガロース:Sigma-Aldrich
臭化エチジウム(EtBr):和光純薬工業
(リアルタイムRT-PCR)
本実施例において、試薬は以下に記載するものを用いた。
TaqMan(登録商標)Reverse Transcription Reagents:Life Technologies
FastStart Universal Probe Master (ROX):Roche
Universal ProveLibrary #64:Roche
Universal ProveLibrary #60:Roche
Forward primer for TS mRNA:Life Technologies
塩基配列:5’-CCC CTT CTT CTC TGG TGG A-3’(配列番号9)
Reverse primer for TS mRNA:Life Technologies
塩基配列:5’-AGG AGT TGC TGT GGT TTA TCA AG-3’(配列番号10)
Forward primer for GAPDH mRNA:Life Technologies
塩基配列:5’-CTC TGC TCC TCC TGT TCG AC-3’(配列番号11)
Reverse primer for GAPDH mRNA:Life Technologies
塩基配列:5’-ACG ACC AAA TCC GTT GAC TC-3’(配列番号12)
実施例1で得られた新規製剤(1)新規製剤(2)及び従来製剤の腫瘍における標的遺伝子抑制効果について、リアルタイムRT-PCR法により評価した。
(In Vivo Imaging Systems:IVIS)
本実施例において、試薬は以下に記載するものを用いた。
ルシフェリン:和光純薬工業
PBS:日水製薬
Lucを標的とするshRNA(以下、「Luc-shRNA」と記載する)は、以下の配列を有する。
Luc-shRNA:
5’-CUUACGCUGAGUACUUCGAUAGUGCUCCUGGUUGUCGAAGUACUCAGCGUAAGUU-3’(配列番号13)
上記実施例1と同様に調製した、TS-shRNAを担持するリポプレックス(新規製剤(2))の卵巣がん腹膜播種に対する治療効果について評価した。
上記実施例1と同様に調製した、TS-shRNAを担持するリポプレックス(新規製剤(2))の膵臓癌腹膜播種に対する治療効果について評価した。
Claims (15)
- ジオレイルホスファチジルエタノールアミン(DOPE)、ホスファチジルコリン及びカチオン性脂質ならびにRNAi分子を含むリポプレックスの製造方法であって、
(a)ジオレイルホスファチジルエタノールアミン(DOPE)、ホスファチジルコリン及びカチオン性脂質をアルコール中に溶解する工程、
(b)RNAi分子を溶解した溶液に、撹拌下、(a)で得られたアルコール溶液を滴下する工程、及び
(c)(b)で得られた溶液を凍結乾燥する工程、
を含み、該ホスファチジルコリンが以下の(i)-(iii)より選択される一以上の特徴を有する:
(i)炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(ii)シス型の炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(iii)相転移温度が0℃未満、
上記方法。 - カチオン性脂質がO,O’-ジテトラデカノイル-N-(α-トリメチルアンモニオアセチル)ジエタノールアミンクロリド(DC-6-14)である、請求項1に記載の方法。
- ホスファチジルコリンが1,2-ジオレオイル-sn-グリセロ-3-ホスホコリン(DOPC)、パルミトイルオエオイルホスファチジルコリン(POPC)、又は1,2-ジエイコセノイル-sn-グリセロ-3-ホスホコリン(DEPC)である、請求項1又は2に記載の方法。
- ホスファチジルコリンがDOPCである、請求項3に記載の方法。
- 工程(a)において、DOPE、DOPC及びDC-6-14をアルコール中に溶解して混合することを含む、請求項1に記載の方法。
- (d)(c)で得られた凍結乾燥物を緩衝液中に混合する工程をさらに含む、請求項1~5のいずれか1項に記載の方法。
- ジオレイルホスファチジルエタノールアミン(DOPE)、ホスファチジルコリン及びカチオン性脂質からなり、該ホスファチジルコリンが以下の(i)-(iii)より選択される一以上の特徴を有する、脂質混合物:
(i)炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(ii)シス型の炭素‐炭素間の二重結合を含む不飽和脂肪鎖を少なくとも一つ含む;
(iii)相転移温度が0℃未満、と
RNAi作用によりチミジル酸合成酵素の発現を抑制することができるショートヘアピンRNA(TS-shRNA)とを含む、胃癌、卵巣癌、及び膵臓癌の腹膜播種転移を治療するための局所投与用医薬組成物。 - カチオン性脂質がO,O’-ジテトラデカノイル-N-(α-トリメチルアンモニオアセチル)ジエタノールアミンクロリド(DC-6-14)である、請求項7に記載の医薬組成物。
- ホスファチジルコリンがDOPCである、請求項7に記載の医薬組成物。
- 脂質混合物がDOPE、DOPC及びDC-6-14からなる、請求項7に記載の医薬組成物。
- DOPE、DOPC及びDC-6-14が、3:2:5のモル比で含まれる、請求項10に記載の医薬組成物。
- shRNAが配列番号8で表される塩基配列からなる、請求項7~11のいずれか1項に記載の医薬組成物。
- 癌化学療法剤と併用される、請求項7~12のいずれか1項に記載の医薬組成物。
- 請求項7~13のいずれか1項に記載の医薬組成物と癌化学療法剤とを含む、組み合わせ物。
- 癌化学療法剤が微小管の脱重合阻害作用を有する抗腫瘍剤、デオキシシチジン誘導体、及びTS阻害作用を有する抗腫瘍剤からなる群から選択される請求項14に記載の組み合わせ物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017118429A RU2671857C1 (ru) | 2014-10-30 | 2015-10-28 | Новый способ производства липоплекса для местного введения и противоопухолевое средство, в котором используется такой липоплекс |
US15/523,222 US9855345B2 (en) | 2014-10-30 | 2015-10-28 | Method for producing lipoplex for topical administration and antitumor agent using such lipoplex |
KR1020177013648A KR101836877B1 (ko) | 2014-10-30 | 2015-10-28 | 국소 투여용 리포플렉스의 신규 제조 방법 및 상기 리포플렉스를 사용하는 항 종양제 |
ES15855798T ES2809460T3 (es) | 2014-10-30 | 2015-10-28 | Nuevo método de producción de lipoplejo para administración local y fármaco antitumoral que utiliza lipoplejo |
EP15855798.3A EP3213755B1 (en) | 2014-10-30 | 2015-10-28 | New production method of lipoplex for local administration and antitumor drug using lipoplex |
JP2015558250A JP5934848B1 (ja) | 2014-10-30 | 2015-10-28 | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 |
AU2015337909A AU2015337909B2 (en) | 2014-10-30 | 2015-10-28 | New production method of lipoplex for local administration and antitumor drug using lipoplex |
CN201580001313.1A CN106232124B (zh) | 2014-10-30 | 2015-10-28 | 制备用于局部施用的脂质体复合物的新方法及使用该脂质体复合物的抗肿瘤剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014221062 | 2014-10-30 | ||
JP2014-221062 | 2014-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016068160A1 true WO2016068160A1 (ja) | 2016-05-06 |
Family
ID=55857495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/080316 WO2016068160A1 (ja) | 2014-10-30 | 2015-10-28 | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9855345B2 (ja) |
EP (1) | EP3213755B1 (ja) |
JP (1) | JP5934848B1 (ja) |
KR (1) | KR101836877B1 (ja) |
CN (1) | CN106232124B (ja) |
AU (1) | AU2015337909B2 (ja) |
ES (1) | ES2809460T3 (ja) |
RU (1) | RU2671857C1 (ja) |
TW (1) | TWI589307B (ja) |
WO (1) | WO2016068160A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022075318A1 (ja) * | 2020-10-08 | 2022-04-14 | 学校法人関西医科大学 | がん治療用組成物の有効性を反映する評価マーカー |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020257537A1 (en) * | 2019-06-18 | 2020-12-24 | Ampersand Biopharmaceuticals, Llc | Transdermal penetrant formulations |
WO2022152939A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007524667A (ja) * | 2004-01-07 | 2007-08-30 | ネオファーム,インコーポレイティド | 脂質組成物及びその使用 |
JP2012505913A (ja) * | 2008-10-16 | 2012-03-08 | マリーナ バイオテック,インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
WO2012161196A1 (ja) * | 2011-05-23 | 2012-11-29 | Delta-Fly Pharma株式会社 | チミジル酸合成酵素に対するshRNA分子を含むリポソームおよびその用途 |
WO2013149140A1 (en) * | 2012-03-29 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
WO2013177419A2 (en) * | 2012-05-23 | 2013-11-28 | The Ohio State University | Lipid nanoparticle compositions and methods of making and methods of using the same |
WO2014178152A1 (ja) * | 2013-04-30 | 2014-11-06 | Delta-Fly Pharma株式会社 | 局所投与用リポソームおよびその用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09248182A (ja) | 1996-03-15 | 1997-09-22 | Oyo Seikagaku Kenkyusho | プラスミド包埋多重膜リポソーム |
CA2286177C (en) | 1997-04-07 | 2011-06-21 | Daiichi Pharmaceutical Co., Ltd. | Composition for gene transfer into cells |
US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Dr5 항체 및 그의 용도 |
EP1807050A1 (en) | 2004-11-05 | 2007-07-18 | Novosom AG | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
WO2008074487A2 (en) | 2006-12-19 | 2008-06-26 | Novosom Ag | Lipids and lipid assemblies comprising transfection enhancer elements |
RU2438664C2 (ru) * | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
CA2742776A1 (en) | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable cationic lipids for nucleic acids delivery systems |
JP5687188B2 (ja) | 2009-03-31 | 2015-03-18 | Delta−Fly Pharma株式会社 | チミジル酸合成酵素に対するRNAi分子およびその用途 |
KR102029657B1 (ko) * | 2011-06-08 | 2019-10-08 | 닛토덴코 가부시키가이샤 | 표적 약물 전달체 및 siRNA 활성을 증가시키는 화합물 |
-
2015
- 2015-10-28 RU RU2017118429A patent/RU2671857C1/ru active
- 2015-10-28 KR KR1020177013648A patent/KR101836877B1/ko active IP Right Grant
- 2015-10-28 AU AU2015337909A patent/AU2015337909B2/en active Active
- 2015-10-28 EP EP15855798.3A patent/EP3213755B1/en active Active
- 2015-10-28 JP JP2015558250A patent/JP5934848B1/ja active Active
- 2015-10-28 ES ES15855798T patent/ES2809460T3/es active Active
- 2015-10-28 CN CN201580001313.1A patent/CN106232124B/zh active Active
- 2015-10-28 US US15/523,222 patent/US9855345B2/en active Active
- 2015-10-28 WO PCT/JP2015/080316 patent/WO2016068160A1/ja active Application Filing
- 2015-10-29 TW TW104135644A patent/TWI589307B/zh active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007524667A (ja) * | 2004-01-07 | 2007-08-30 | ネオファーム,インコーポレイティド | 脂質組成物及びその使用 |
JP2012505913A (ja) * | 2008-10-16 | 2012-03-08 | マリーナ バイオテック,インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
WO2012161196A1 (ja) * | 2011-05-23 | 2012-11-29 | Delta-Fly Pharma株式会社 | チミジル酸合成酵素に対するshRNA分子を含むリポソームおよびその用途 |
WO2013149140A1 (en) * | 2012-03-29 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
WO2013177419A2 (en) * | 2012-05-23 | 2013-11-28 | The Ohio State University | Lipid nanoparticle compositions and methods of making and methods of using the same |
WO2014178152A1 (ja) * | 2013-04-30 | 2014-11-06 | Delta-Fly Pharma株式会社 | 局所投与用リポソームおよびその用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022075318A1 (ja) * | 2020-10-08 | 2022-04-14 | 学校法人関西医科大学 | がん治療用組成物の有効性を反映する評価マーカー |
Also Published As
Publication number | Publication date |
---|---|
CN106232124B (zh) | 2018-01-12 |
JPWO2016068160A1 (ja) | 2017-04-27 |
US20170319713A1 (en) | 2017-11-09 |
EP3213755A1 (en) | 2017-09-06 |
EP3213755B1 (en) | 2020-06-24 |
KR20170063962A (ko) | 2017-06-08 |
ES2809460T3 (es) | 2021-03-04 |
AU2015337909A1 (en) | 2017-04-27 |
TW201620504A (zh) | 2016-06-16 |
US9855345B2 (en) | 2018-01-02 |
EP3213755A4 (en) | 2018-07-04 |
RU2671857C1 (ru) | 2018-11-07 |
CN106232124A (zh) | 2016-12-14 |
TWI589307B (zh) | 2017-07-01 |
JP5934848B1 (ja) | 2016-06-15 |
AU2015337909B2 (en) | 2018-12-13 |
KR101836877B1 (ko) | 2018-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE48887E1 (en) | RNA interference compositions and methods for malignant tumors | |
US10792251B2 (en) | Liposomal particles, methods of making same and uses thereof | |
Resnier et al. | Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse | |
JP5941460B2 (ja) | チミジル酸合成酵素に対するshRNA分子を含むリポソームおよびその用途 | |
US20180185284A1 (en) | Nanoliposomal c-MYC-siRNA Inhibits In Vivo Tumor Growth of Cisplatin-Resistant Ovarian Cancer | |
JP5934848B1 (ja) | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 | |
JP6307070B2 (ja) | 局所投与用リポソームおよびその用途 | |
KR101949507B1 (ko) | Kras를 표적으로 하는 핵산 함유 약제학적 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2015558250 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15855798 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015337909 Country of ref document: AU Date of ref document: 20151028 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15523222 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20177013648 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015855798 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017118429 Country of ref document: RU Kind code of ref document: A |